

Sample ID: **ACTN01029999T** | Gender: **Male** | Birth year: **1950**

Summary

Patient clinical history (11-Oct-2021)

| | |
|-------------------------------------|---|
| Relevant systemic treatment history | Vemurafenib (2020), Ipilimumab (2021) |
| Other oncological history | Surgery (2019) |
| | Previous primary tumor: Bone/Soft tissue Schwannoma (2018, considered active) |
| Relevant non-oncological history | Pancreatitis, Myocardial infarction |

Patient current details (11-Oct-2021)

| | |
|--------------------------------------|------------------------|
| WHO status | 1 |
| Unresolved toxicities grade => 2 | Fatigue (2), Dizziness |
| Significant infection | No |
| Significant aberration on latest ECG | Atrial arrhythmia |
| Cancer-related complications | Ascites |

Laboratory (11-Oct-2021)

| | | | |
|-----------------|-----------------|--------------------------------|--|
| Liver function | Total bilirubin | | |
| | ASAT | (< 33 U/l) | 36 U/l (no trend information available) |
| | ALAT | | |
| | ALP | | |
| | Albumin | | |
| Kidney function | Creatinine | | |
| | CKD-EPI eGFR | (> 100 mL/min) | > 100 mL/min (21-Sep-2021) |
| Other | Hemoglobin | (6.5 - 9.5 mmol/L) | 5.5 mmol/L (no trend information available) |
| | Thrombocytes | (155 - 350 10 ⁹ /L) | 150 10 ⁹ /L (out of range for 2 cons. measurements, trend down) |

Tumor details (11-Oct-2021)

| | |
|---------------------------------------|--|
| Stage | IV |
| Primary tumor location | Skin |
| Primary tumor type | Melanoma |
| Biopsy location | Liver |
| Lesions in CNS / Brain / Bone / Liver | Yes (active, not symptomatic) / No / Unknown / Yes |
| Other lesions | Pulmonal, Abdominal |
| Measurable disease (RECIST) | Yes |

Molecular results

| | |
|---|--------------|
| Molecular results have reliable quality | Yes |
| Actionable molecular events | BRAF p.V600E |

Conclusion

Coming soon

Treatments

Coming soon